← Back to Clinical Trials
Recruiting NCT05205291

Molecular Imaging of Inflammation in Parkinson's Disease Using LPS and TSPO-PET/MR

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Neurodegenerative Diseases
Sponsor University of Exeter
Study Type OBSERVATIONAL
Phase N/A
Enrollment 30
Sex ALL
Min Age 50 Years
Max Age 85 Years
Start Date 2022-02-28
Completion 2026-08-31
Interventions
LipopolysaccharidePET/MR with [11C]PBR28

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

It is not known what causes Parkinson's disease and what makes it worsen over time. Research conducted in the past few years has highlighted the possible role of inflammation on this process but its actual mechanisms are still obscure. In this study, the investigators aim to gain understanding on how inflammation is increased in Parkinson's disease and what are its mechanisms, by performing two Positron Emission Tomography (PET) scans using the tracer \[11C\]PBR28, that takes pictures of the brain highlighting the areas of inflammation, before and after the administration of a compound called Lipopolysaccharide or LPS, that is known to cause a mild degree of inflammation. The investigators will couple this study with two venous blood draws to measure the levels of circulating molecules of inflammation.

Eligibility Criteria

Inclusion Criteria (all): * 50-85 years of age, male or female * Able to give informed consent * Adequate visual and auditory acuity to complete the neuropsychological testing * No presence or history of significant neurological or psychiatric disorders * BDI ≥ 20, moderate depression * No presence or history of inflammatory or autoimmune disorders * Negative family history for neurodegenerative diseases * Cognitively healthy (i.e., education-adjusted MoCA total score ≥ 26 points at screening) * Female subjects must either be documented by medical records or physician's note to be either surgically sterile (by means of hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or post-menopausal for at least 1 year (no menses for 12 months without an alternative medical cause) or if they are of childbearing potential, they must commit to use of a highly effective contraceptive measure for the duration of the study and a minimum of six months following the PET scan (including com

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}